Schelleman H, Klungel O H, van Duijn C M, Witteman J C M, Hofman A, de Boer A, Stricker B H Ch
Department of Epidemiology & Biostatistics, Erasmus MC, Rotterdam, The Netherlands.
Br J Clin Pharmacol. 2005 Apr;59(4):483-5. doi: 10.1111/j.1365-2125.2004.02332.x.
We investigated whether the insertion/deletion (I/D) polymorphism of the ACE gene modified the adherence to ACE inhibitors as measured by the discontinuation of an ACE inhibitor, or addition of another antihypertensive drug.
This was a cohort study among 239 subjects who started ACE inhibitor therapy. A Cox proportional hazard model was used to calculate relative risk (RR).
During follow-up there was no significant difference between subjects with the DD, ID or II genotype (DD vs II; RR = 1.17, 95%CI: 0.78, 1.77 and ID vs II; RR = 1.06, 95%CI: 0.73, 1.55) in adherence.
The I/D polymorphism of the ACE gene does not influence the adherence to ACE inhibitors.
我们研究了血管紧张素转换酶(ACE)基因的插入/缺失(I/D)多态性是否会通过停用ACE抑制剂或添加另一种抗高血压药物来衡量对ACE抑制剂的依从性产生影响。
这是一项针对239名开始接受ACE抑制剂治疗的受试者的队列研究。采用Cox比例风险模型计算相对风险(RR)。
在随访期间,DD、ID或II基因型受试者(DD与II相比;RR = 1.17,95%置信区间:0.78,1.77;ID与II相比;RR = 1.06,95%置信区间:0.73,1.55)在依从性方面没有显著差异。
ACE基因的I/D多态性不影响对ACE抑制剂的依从性。